The pan-Canadian Pharmaceutical Alliance (pCPA) updated the status of negotiations on brand name drugs as of April 30, 2016:

• 23 negotiations are currently underway with 5 files added since the last update on March 31, 2016:
  • Arnuity Ellipta (fluticasone furoate): used for the treatment of asthma;
  • Breo Ellipta (fluticasone furoate/vilanterol): used for treatment of asthma;
  • Rosiver (ivermectin): used to treat rosacea;
  • Technivie (ombitasvir/paritaprevir/ritonavir): used for the treatment of Hepatitis C; and
  • Zepatier (elbasvir grazoprevir): used for the treatment of Hepatitis C.

• 105 joint negotiations have been completed with 5 files completed since the last update on March 31, 2016:
  • Jardiance (empagliflozin): used to treat Type 2 diabetes mellitus;
  • Tobi Podhaler (tobramycin): used for the management of cystic fibrosis;
  • Tradjenta (linagliptin) and Jentadueto (linagliptin/metformin): used to treat Type 2 diabetes mellitus;
  • Xeljanz (tofacitinib): used to treat rheumatoid arthritis; and
  • Simponi (golimumab) IV: used to treat rheumatoid arthritis.

Please note: Negotiations involving Simponi were closed as an agreement was not reached.

• 37 drug products for which the pCPA has decided not to negotiate collectively or individually at the provincial-territorial level with no new files added since the last update on March 31, 2016.

• 13 negotiations for brand name drug products have been recommended by the pCPA to be considered by each Province/Territory individually with 1 new file added since the last update on March 31, 2016:
  • Humalog 200 units/ml (insulin lispro): used to treat Type 1 and 2 diabetes

For more information, please consult the pCPA’s website.